US FDA approves Amgen's Uplizna as first treatment for rare immune disorder
The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares ...
FDA suspends program to improve bird flu testing due to staff cuts
The U.S. Food and Drug Administration is suspending efforts to improve its bird flu testing of milk, cheese and pet food due ...
GSK resolves patent lawsuit against Pfizer over RSV vaccines
British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory ...
Amgen Inc. stock underperforms Thursday when compared to competitors despite daily gains
Shares of Amgen Inc. AMGN rallied 1.36% to $309.85 Thursday, on what proved to be an all-around dismal trading session for ...
US FDA approves expanded use of Amgen's rare disease drug
The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares ...
Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Medscape9h
PBM Private Labeling Boosts Biosimilar Adoption, Raises Anticompetitive Concerns
Co-production deals with adalimumab biosimilar manufacturers and PBMs have increased biosimilar adoption, but this ...
Medscape13h
Is Percent Weight Loss the Right Obesity Treatment Target?
New evidence suggests that factors other than the percentage of weight loss should be considered when determining the success ...
Amgen gets expanded FDA label approval for Uplizna
Amgen ( NASDAQ: NASDAQ: AMGN) announced that the U.S. Food and Drug Administration (FDA) has granted an expanded label ...
Amgen stock rises following FDA approval of UPLIZNA
The FDA’s decision to grant Breakthrough Therapy Designation to UPLIZNA underscores the significant unmet medical need in ...
FDA Approves Second Indication for Amgen's Immune System Treatment Uplizna
Amgen said the Food and Drug Administration approved Uplizna for Immunoglobulin G4-related disease, the second approved indication. The biotechnology company said Thursday the FDA granted breakthrough ...
UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE
Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA as the first and only treatment for adults living with Immunoglobulin G4-related disease (IgG4 ...